Neurology, distilled.
Landmark trials with structured baseline tables. Real-world cases with discussion. Specialty references, board prep, and a journal-club reading list — built and maintained by clinicians, free for the community.
Everything a neurologist needs, in one place.
Each section is built around clinical workflow — references for service, prep for boards, discussion for tough cases, and the evidence base behind every decision.
NeuroTrials
Search 850+ landmark trials with structured baseline tables, exclusion criteria, and AI-assisted summaries.
Search trials →
NeuroWiki
Specialty reference pages — pathophysiology, diagnostic frameworks, and evidence-based management, curated by clinicians.
Open the wiki →
NeuroResidents
On-call templates, neuro-exam frameworks, summaries, and clinical pearls organised by rotation.
Open the resident library →
NeuroJournal
Curated reading list. New articles from JAMA Neurology, Stroke, Neurology, and Lancet Neurology — distilled into 5-minute summaries.
Browse the journal →
NeuroBoards
Practice questions, flashcards, study notes, and progress tracking — for RITE, boards, and continuing education.
Start prep →
NeuroCasesNEW
Members share real-world cases with images, polls, and discussion. Vote on next steps, learn from outcomes, build the community.
Browse cases →Recently added trials
The most recent landmark trials reviewed across all 9 specialties — structured summaries, baseline tables, and exclusion criteria.
To assess the efficacy and safety of adjunctive tirofiban after successful endovascular reperfusion in patients with acute ischaemic stroke due to anterior-circulation large-vessel occlusion.
Functional independence (mRS 0-2) at 90 days: 49% (340/689) tirofiban vs 43% (299/691) placebo (absolute risk difference 6.1 percentage points, 95% CI 0.8-11.3, p=0.023; adjusted RR 1.15, 95% CI 1.03-1.27, p=0.0092)
View Summary →Test whether adding biomarker-matched targeted therapy (erlotinib, everolimus or dasatinib) to standard radiotherapy improves overall survival in newly diagnosed, biopsy-proven diffuse intrinsic pontine glioma (DIPG).
Primary endpoint NOT met: median OS not improved over historical control in any arm (trial OS 11.1 mo vs historical 10.8 mo); trial stopped for futility.
View Summary →To assess the safety and efficacy of direct transfer to angiography suite (DTAS) versus conventional pathway (imaging first) in patients with acute severe neurological deficit highly suggestive of ischaemic stroke due to large vessel occlusion (ASND-LVO).
Trial stopped early for safety after interim analysis
View Summary →To assess whether low-dose acetazolamide improves gait function compared with placebo in patients with idiopathic normal pressure hydrocephalus (iNPH) awaiting ventriculoperitoneal shunt surgery.
Acetazolamide did not improve gait vs placebo: adjusted between-group difference in composite gait score change was 0.09 units (95% CI -3.61 to 3.79, p=0.96)
View Summary →To evaluate the safety and efficacy of staged, bilateral magnetic resonance-guided focused ultrasound (MRgFUS) pallidothalamic tractotomy for motor complications of Parkinson's disease in a prospective multicentre setting.
Median bilateral upper and lower extremity (ULE) motor scores decreased from 33.0 (IQR 28.0-40.5) at baseline to 21.0 (15.0-25.5) at 3 months post-bilateral treatment, a 32% improvement (IQR 18-52, p<0.0001)
View Summary →To assess whether decompressive craniectomy improves functional and safety outcomes compared with standard craniotomy in patients with large acute epidural haematoma complicated by tentorial herniation.
Decompressive craniectomy did NOT improve 6-month functional outcomes vs standard craniotomy (common OR 0.79, 95% CI 0.41–1.58; p=0.51)
View Summary →To evaluate whether remote ischaemic conditioning (RIC) improves 90-day functional outcomes in patients with acute supratentorial intracerebral haemorrhage (ICH) not requiring surgical intervention.
RIC did NOT improve 90-day favourable outcome (mRS 0-2): 68.1% (RIC) vs 71.2% (sham); adjusted RR 0.97, 95% CI 0.87-1.08, p=0.61
View Summary →To evaluate the efficacy and safety of a tocotrienol-rich vitamin E complex (HOV12020) for preventing clinical progression in patients with CADASIL, the most common monogenic small vessel disease with no available disease-modifying therapy.
Treatment failure occurred in 68.0% of HOV12020 group vs 61.5% of placebo group (both exceeded the 40% expected placebo event rate)
View Summary →NeuroJournal — this week's picks
High-yield new articles from JAMA Neurology, Stroke, Neurology, and Lancet Neurology — distilled into 5-minute summaries.
A staged, evidence-based framework for Parkinson's treatment: when to start levodopa, how to manage motor fluctuations and dyskinesia, and when and how to choose among the three advanced modalities —…
More than a dozen disease-modifying therapies, five mechanistic classes, and few head-to-head trials. A structured framework for choosing in MS: efficacy tiers and the limits of cross-trial comparison, the differences…
After two decades stuck against epilepsy's drug-resistance ceiling, the modern era delivered genuinely better molecules, mechanisms beyond ion channels, and the first epilepsy gene-regulation therapy with disease-modifying signals. From cenobamate's…
Six FDA-approved biologics now compete for the same generalized myasthenia gravis patient — three complement inhibitors, three FcRn antagonists, and not a single head-to-head trial to guide us. The "refractory…
For two decades, Alzheimer therapy meant cholinesterase inhibitors and memantine. Two FDA-approved anti-amyloid antibodies — lecanemab and donanemab — now slow cognitive decline by 27–35% over 18 months, and brexpiprazole…
For four decades, "detoxify first" was the unquestioned dogma of medication overuse headache. Six RCT datasets and a 2025 network meta-analysis have now made that position genuinely difficult to defend.…
Four randomized trials appeared to close the door on distal vessel thrombectomy — but their negative results reflected patient selection failures, not biological limits. ORIENTAL MEVO and DISTALS demonstrate what…
This week's wiki picks
A rotating set of reference pages across specialties — pathophysiology, diagnostic frameworks, and management. New picks every week.
Congenital Myopathies Congenital myopathies are a heterogeneous group of inherited muscle disorders defined by characteristic structural abnormalities on muscle biopsy and onset typically at birth or early infancy. The pooled prevalence across…
Read Full Article →Circumscribed astrocytic gliomas are pediatric and young adult tumors that grow as well-defined, often cystic masses rather than infiltrating diffusely. The 2021 WHO classification recognizes them as a distinct group, separated from…
Read Full Article →Neuropharmacology is the application of pharmacologic principles to the nervous system. It sits at the intersection of basic neuroscience, clinical neurology, and pharmacology — and shapes nearly every clinical decision the neurologist…
Read Full Article →Autonomic disorders span a wide clinical territory — from common diabetic autonomic neuropathy to rare familial dysautonomia. Diagnostic workup requires systematic evaluation of the autonomic nervous system, identification of patterns of dysfunction…
Read Full Article →Third Nerve Palsy Third nerve (oculomotor) palsy is among the most clinically consequential cranial neuropathies encountered in neurological practice. The oculomotor nerve subserves the majority of extraocular movements, eyelid elevation, and parasympathetic…
Read Full Article →Atypical Presentations of Alzheimer Disease Alzheimer disease (AD) is most commonly associated with an amnestic phenotype in which progressive episodic memory loss is the predominant early feature. However, a significant minority of…
Read Full Article →NSGC Guideline: Genetic Testing & Counseling for Unexplained Epilepsies (2023) This topic summarizes the 2022 National Society of Genetic Counselors (NSGC) evidence-based practice guideline on genetic testing and counseling for individuals with…
Read Full Article →Recent NeuroCases
Cases shared by members — discuss, vote, learn from outcomes.
Ahmed Koriesh · 4 weeks ago
76F, baseline mRS 1, AF on sub-therapeutic warfarin, global aphasia with R-sided hemiplegia. NCCT ASPECTS 3, left M1 occlusion, LKW 15 h ago. Late window — pull straight to angio or get CTP first?
Ahmed Koriesh · 4 weeks ago
62F on apixaban, aphasia LKW Tuesday 6 PM, worsened Wednesday noon (18h). NIHSS 16, M3 anterior division occlusion, favorable mismatch. Late window — what do you do?
YOUR TURN Post a Case Share your case. Let the community help with decision-making. Sign in to postOpen library. Closed community.
Anyone can read. Members — verified clinicians and trainees — can post cases, comment, vote, and contribute to the wiki. No ads. No paywalls.
Every trial summary, wiki page, case, and journal article is open — no signup required.
Free registration for clinicians and trainees. Post cases, comment, vote in polls, add wiki content.
Your name, photo, position, and institution appear on everything you contribute — build your clinical brand.
Built by clinicians. Maintained by the community.
Founded and maintained by Dr. Ahmed Koriesh, Stroke Director at Cleveland Clinic Florida. Powered by 507 clinician members who contribute, vet, and discuss.